Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer
Authors:
Open Access
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (1) , 116-125
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?Journal of Thoracic Oncology, 2012
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and PerspectivesJapanese Journal of Clinical Oncology, 2010
- Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapyRadiation Oncology, 2010
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Cryptogenic fibrosing alveolitis and lung cancer: the BTS studyThorax, 2009
- Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgeryEuropean Journal of Cardio-Thoracic Surgery, 2008
- Fleischner Society: Glossary of Terms for Thoracic ImagingRadiology, 2008
- Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumorsRadiation Oncology, 2007
- Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring.American Journal of Roentgenology, 1997